Guy Macdonald Purchases Shares in SCYNEXIS, Inc.
Guy Macdonald acquired 2,875 shares of SCYNEXIS, Inc. on June 26, 2026.
Key Points
- Guy Macdonald purchased 2,875 shares of SCYNEXIS, Inc. on June 26, 2026, with shares trading at $4.07.
- SCYNEXIS, Inc. has a market cap of $40.4 million and a beta of 1.063, with shares ranging from $3.68 to $10.48 over the past year.
- Several funds, including Squadron Capital and Heights Capital, opened new positions in SCYNEXIS, Inc., while analysts maintain a positive outlook.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guy Macdonald recently purchased 2,875 shares of SCYNEXIS, Inc. (NasdaqCM: SCYX) on June 26, 2026. The transaction was not planned under a Rule 10b5-1 trading plan. Shares of SCYNEXIS were trading at $4.07 on Wednesday.
Insider Buying and Selling at SCYNEXIS, Inc.
On June 26, 2026, several insiders, including Guy Macdonald, bought 2,875 shares each of SCYNEXIS, Inc. These transactions were not made under a pre-planned trading program. Other insiders making similar purchases on the same day include Armando Anido, Ann Hanham, Brian Philippe Tinmouth, and David Hastings.
Other Institutional Activity in SCYNEXIS, Inc.
Several institutional investors have also shown interest in SCYNEXIS, Inc. Squadron Capital Management LLC opened a new position with 7,608,695 shares valued at approximately $6.98 million. Similarly, Heights Capital Management, Inc. initiated a stake with 2,086,960 shares worth about $1.91 million. Avidity Partners Management LP maintained its position with 2,081,660 shares valued at $1.91 million. Kingdon Capital Management, L.L.C. and Empery Asset Management, LP also opened new positions with 1,982,491 and 1,847,826 shares, respectively.
SCYNEXIS, Inc. Stock Down 22.2%
Shares of SCYNEXIS, Inc. traded near $4.07 on Wednesday. The company has a market cap of approximately $40.4 million and a beta of 1.063. Over the past 52 weeks, the stock has ranged from $3.68 to $10.48. The 50-day moving average is $5.88, while the 200-day moving average stands at $6.13. SCYNEXIS maintains a current ratio of 3.943 and a quick ratio of 3.727, with a debt-to-equity ratio of 4.989.
$SCYX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on SCYNEXIS, Inc. On October 28, 2025, Guggenheim maintained a 'buy' rating with a price target of $3.00. Ladenburg Thalmann & Co. also maintained a 'buy' rating with a target of $7.50 on May 10, 2024. Overall, the consensus among analysts is favorable, with a mean price target of $33.55 based on three opinions.
About SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company based in Jersey City, New Jersey. It focuses on developing treatments for difficult-to-treat and drug-resistant fungal infections. The company markets BREXAFEMME for vulvovaginal candidiasis and is developing SCY-247 for invasive fungal infections, currently in Phase I clinical trials. Led by CEO Dr. David Gonzalez Angulo, SCYNEXIS employs around 18 people.
Bottom Line
Guy Macdonald's recent purchase of SCYNEXIS shares reflects ongoing interest in the company from insiders. Institutional investors are also opening new positions, suggesting confidence in the company's future. However, investors should remember that insider and institutional trades are historical data and may not indicate current positions.
Get SCYNEXIS, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SCYX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.